Accropeutics
Latest round
- Series C
Last raised
- May 2026
Total raised
- $114M
Investors
- 13
About Accropeutics
Based in Suzhou, China and founded in 2017, Accropeutics operates as a provider of small molecule innovative medicine that focuses on the research and development of necroptosis inhibitor. The company has acquired more than 10 patents, and has been rated as a Technology-based SMEs.D. in Chemistry from the State University of New Jersey and worked at Neurocrine Biosciences.D. in Biochemistry and Molecular Biology from Peking Union Medical College. She was a professor at Soochow University and a researcher at the Suzhou Institute of Systems Medicine. Accropeutics is mainly engaged in the research and development of necroptosis inhibitor. The core technology is a new drug development platform targeting regulated cell death. Products include RIPK1 inhibitor AC-003, RIPK2 inhibitor AC-101, highly selective TYK2/JAK1 inhibitor AC-201, etc. Its platform and products focus on diseases such as inflammation, fibrosis, autoimmune diseases and cancer. The company generates revenue by providing new medicines for the treatment of inflammation, fibrosis, autoimmune diseases and cancer.
Who invested in Accropeutics
13 investors across 3 rounds
See all investors in Accropeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Accropeutics
Who invested in Accropeutics?
Accropeutics has 13 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Accropeutics raised?
Accropeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Accropeutics last raise money?
Accropeutics's most recent round on record is a Series C, in May 2026.
What does Accropeutics do?
Based in Suzhou, China and founded in 2017, Accropeutics operates as a provider of small molecule innovative medicine that focuses on the research and development of necroptosis inhibitor.
Where is Accropeutics headquartered?
Accropeutics is headquartered in Suzhou, China.
Which VCs invest in companies like Accropeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Accropeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Accropeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.